Kumiko Yamashima
Kyoto Prefectural University of Medicine
Cell therapyEphrinReceptorKinaseChemistryApoptosisImmunologyIn vivoChemotherapyNeuroblastomaCyclophosphamideImmunotherapyTrametinibFludarabineRhabdomyosarcomaMEK inhibitorStem cellToxicityMalignant transformationChimeric antigen receptorCancer researchMAPK/ERK pathwayCell growthMedicinePharmacology
2Publications
1H-index
1Citations
Publications 3
Newest
#1Akimasa Tomida (Kyoto Prefectural University of Medicine)H-Index: 1
#2Shigeki Yagyu (Kyoto Prefectural University of Medicine)H-Index: 14
Last. Tomoko Iehara (Kyoto Prefectural University of Medicine)H-Index: 21
view all 8 authors...
Disialoganglioside (GD2)-specific chimeric antigen receptor (CAR)-T cells (GD2-CAR-T cells) have been developed and tested in early clinical trials in patients with relapsed/refractory neuroblastoma. However, the effectiveness of immunotherapy using these cells is limited, and requires improvement. A combinatorial therapy with CAR-T cells and molecular targeted drugs could be a promising strategy to enhance the antitumor efficacy of CAR T-cell immunotherapy. Here, we generated GD2-CAR-T cells vi...
Source
#1Hiroshi Kubo (Kyoto Prefectural University of Medicine)H-Index: 1
#2Shigeki Yagyu (Kyoto Prefectural University of Medicine)H-Index: 14
Last. Hajime Hosoi (Kyoto Prefectural University of Medicine)H-Index: 33
view all 9 authors...
Abstract Ephrin type-B receptor 4 (EPHB4), expressed in tumors including rhabdomyosarcoma, is a suitable target for chimeric antigen receptor (CAR)-T cells. Ligand independent activation of EPHB4 causes cell proliferation and malignant transformation in rhabdomyosarcoma, whereas ligand-dependent stimulation of EPHB4 induces apoptosis in rhabdomyosarcoma. Therefore, we hypothesized that ligand-based EPHB4-specific CAR-T cells may kill rhabdomyosarcoma cells without stimulating downstream cell pro...
1 CitationsSource
Objectives null Chimeric antigen receptor (CAR)-T cell therapy possesses the potential to cause unexpected on-target toxicities that may be life-threatening. Non-human primates (NHPs) share considerable structural homology and expression profiles of most proteins with humans and are therefore utilised as an animal model for non-clinical safety studies. We have developed a lymphodepleted NHP model by conditioning the animals with immunosuppressive chemotherapy designed to simulate clinical practi...
Source